Mobilization and Collection of Peripheral Blood Stem Cells in Multiple Myeloma Patients Older Than 65 Years

Roncón, Susana; Barbosa, I.L.; Campilho, Fernando; Lopes, Sérgio; Campos, António; Carvalhais, Alzira

doi:10.1016/j.transproceed.2010.12.031

Cited by 10 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The population of candidates to hematopoietic transplantation is continuously growing, also including individuals over 60 years of age and carrying comorbidities. The above‐reported recommendations in the autologous setting hold also for elderly patients and for patients with comorbidities, such as coronary artery disease, since PBPC mobilization and collection proved safe also in such subgroups 35,94,95 . However, evidence is still lacking as well as the availability of good retrospective analyses for specific clinical settings, and thus the panel could not provide specific recommendations for these issues.…”

Section: Discussionmentioning

confidence: 99%

Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In fact, we generally use a threshold value of 10/µL CD34+ PBSCs in our center. Despite the decrease in the number of collected CD34 + cells with increasing age, sufficient PBSC yield for ≥1 AHSCT can usually be obtained from elderly patients up to 69–72 years …”

Section: Factors Affecting Successful Mobilization Of Pbscs In MMmentioning

confidence: 99%

Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma

Şahin

Demirer

2017

J of Clinical Apheresis

View full text Add to dashboard Cite

Multiple myeloma (MM) is the leading indication of autologous hematopoietic stem cell transplantation (AHSCT) worldwide. The collection of PBSCs is the essential step for AHSCT. The limits for minimum and optimum CD34 cells collected have been accepted as 2 × 10 /kg and ≥4 × 10 /kg for single AHSCT; 4 × 10 /kg and ≥8-10 × 10 /kg for double AHSCT. Despite the success of conventional methods for PBSC mobilization in MM, mobilization failure is still a concern depending on patient age, duration of disease, and the type of induction therapy. By definition, "proven poor mobilizer" is the occurrence of mobilization failure (CD34+ cell peak <20/µL peripheral blood) after adequate preparation (after 6 days of G-CSF 10 µg/kg body weight alone or after 20 days of G-CSF >5 µg/kg body weight following chemotherapy) or a CD34+ cell yield of <2.0 × 10 /kg body weight after three consecutive apheresis. "Predicted poor mobilizer" involves (1) a failure of a previous collection attempt OR (2) a previous history of extensive radiotherapy or full courses of therapy affecting mobilization OR (3) the presence of at least two of the following features: advanced disease (>2 lines of chemotherapy), refractory disease, extensive bone marrow involvement or cellularity of 30% at the time of mobilization or age >65 years. This article aims at discussing the risk factors for mobilization failure in the era of novel antimyeloma drugs, defining the poor mobilizer concept and summarizing the current and future strategies for the prevention and management of mobilization failures in MM.

show abstract

“…While some reports have suggested that older patients can have a somewhat lower CD34 + yield, older age does not seem to have any clinically relevant impact on haematopoietic cell mobilization. Generally, older patients should not be considered to have a higher risk of mobilization failure than younger patients, particularly with the use of novel mobilization strategies, such as the CXCR4 antagonist plerixafor (Siegel et al, 1999;Morris et al, 2003;Fietz et al, 2004;Jantunen et al, 2006;Tempescul et al, 2010;Roncon et al, 2011;Micallef et al, 2013).…”

Section: Melphalan Dose and Comorbiditiesmentioning

confidence: 99%

Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma

Auner

Garderet

2015

Br J Haematol

View full text Add to dashboard Cite

SummaryHigh-dose chemotherapy with melphalan followed by autologous haematopoietic cell transplantation (AHCT) is a standard of care in young patients (<65 years) with multiple myeloma. Most myeloma patients, however, are older than 65 years at the time of diagnosis, and the findings of numerous single-centre and registry studies provide evidence that AHCT can be a feasible and effective treatment option in these patients. Nevertheless, AHCT is not generally recommended as standard treatment in the elderly, due to the fact that a benefit of AHCT over conventional-dose therapy has not been demonstrated by prospective randomized trials. Yet, the use of AHCT has increased substantially in older patients in recent years, and an increasing number of reports suggest comparable outcomes for older and younger patients after AHCT. In this review we summarize the results of AHCT for elderly patients with multiple myeloma.

show abstract

Mobilization and Collection of Peripheral Blood Stem Cells in Multiple Myeloma Patients Older Than 65 Years

Cited by 10 publications

References 6 publications

Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process

Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process

Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma

Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma

Contact Info

Product

Resources

About